DRUG WARNING: ETRAVIRINE (INTELENCE)

By /

On October 15, 2009, Tibotec, a division of Janssen-Ortho Inc., in collaboration with Health Canada, issued a Dear Healthcare Professional letter to relay important safety information for Intelence (etravirine).  The letter strengthens warnings and precautions for severe skin reactions to reflect post-marketing reports of:

  • a fatality due to toxic epidermal necrolysis
  • hypersensitivity reactions, sometimes accompanied by hepatic failure

Intelence should be discontinued immediately if signs or symptoms of severe skin rash or hypersensitivity reactions occur.  Clinical status and liver transaminases should be monitored and treated appropriately.  Delays in discontinuing Intelence treatment after the appearance of a severe rash or hypersensitivity reaction may lead to a life-threatening reaction.

For more information: Click here to download the Warning letter issued by Tibotec

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below

Laboratory Order Forms

Start typing and press enter to search